Connect with us

Health

AbbVie Inc (NYSE:ABBV) Major Events From The Third Quarter

Published

on

AbbVie Inc (NYSE:ABBV) reported positive top-line data from three pivotal Phase III clinical trials assessing risankizumab, an investigational IL-23 inhibitor, compared to adalimumab and ustekinumab for the treatment of people with moderate-to-severe chronic plaque psoriasis.

Data of the three studies demonstrated that risankizumab fulfilled all co-primary and graded secondary endpoints, attaining considerably greater rates of almost clear or clear skin at week 16 compared to adalimumab and ustekinumab. The safety profile was steady with all previously reported trials, and there were no fresh safety indications detected across the three trials. Risankizumab is being advanced in collaboration with Boehringer Ingelheim.

The key events

AbbVie reported positive top-line data from the Phase III SELECT-BEYOND clinical study assessing upadacitinib, in patients with moderate-to-severe rheumatoid arthritis who failed to adequately respond or were not tolerant to treatment with biologic DMARDs.

Data demonstrated that following 12-weeks of treatment, both once-daily administration of upadacitinib (30 mg and 15 mg) met the trial’s main endpoints of low disease activity and ACR20. All ranked secondary endpoints were attained with both measures. The safety profile of upadacitinib was steady with previously announced Phase 2 studies and the Phase III SELECT-NEXT clinical study, with no new safety indications detected. Detailed study outcomes will be presented at an imminent medical conference.

AbbVie reported positive top-line data from the Phase IIb randomized, placebo-controlled, dose-ranging trial of upadacitinib in adult people with moderate-to-severe atopic dermatitis not adequately checked by topical treatments, or for whom such treatments were not medically suggested. Results in all doses at week 16 demonstrated that patients cured with upadacitinib attained statistically notable improvements, versus placebo, in the primary and all itch-specific and skin secondary endpoints. In addition, reduction in itch was seen within the initial week and improvement in skin within the preliminary two weeks.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized1 day ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health2 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business2 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business2 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business2 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP2 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP2 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP2 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

INDUSTRIAL HEMP2 weeks ago

Kush Bottles Inc (OTCMKTS:KSHB)’ Q1 Results For Fiscal Year 2018 Released

Leading supplier and service provider to the cannabis sector, Kush Bottles Inc (OTCMKTS:KSHB), has released financial results for 2018’s first...

INDUSTRIAL HEMP2 weeks ago

Wanderport Corp. (OTCMKTS:WDRP) Will Accept The Use Of Bitcoin In Its E-Commerce Store

Wanderport Corp. (OTCMKTS:WDRP) has made good its promise of allowing full access to the Company’s full suite of products. The...

Advertisement
Advertisement